+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 67 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.

Age: 18Years +All GendersPhase 3
206 locations
O

Actively Recruiting

This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.

Age: 18Years - 100YearsAll Genders
141 locations
O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
C

Actively Recruiting

Researchers are evaluating treatments for advanced HRD-positive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, and clear cell carcinoma of the ovary in patients who have no residual tumor after primary tumor debulking. This phase II, multicenter, randomized, open-label study compares the recurrence-free survival of patients receiving either 3 cycles of carboplatin plus paclitaxel followed by maintenance therapy with niraparib or 6 cycles of the same chemotherapy plus niraparib maintenance. The study includes patients with specific disease stages FIGO IIIA to IV and uses genetic testing to stratify patients based on tumor characteristics.

Age: 18Years +FEMALEPhase 2
50 locations
C

Actively Recruiting

Researchers are evaluating treatments for adults with high risk chronic lymphocytic leukemia CLL, a common and aggressive form of leukemia. The study compares a triple drug combination of acalabrutinib, obinutuzumab, and venetoclax GAVe against a dual combination of obinutuzumab and venetoclax GVe. This phase 3 trial aims to see if adding acalabrutinib can prolong the time patients live without disease progression, focusing on patients with specific genetic risk factors like 17p deletion, TP53 mutation, or complex karyotype. Participants receive infusions of obinutuzumab on specific days during the first six cycles, along with oral venetoclax taken daily with increasing doses during the initial cycles and then a fixed dose for up to 12 cycles. Those in the triple combination group also take oral acalabrutinib twice daily for cycles 15 to 24. Treatments are given in cycles lasting several weeks, with precise dosing schedules for each medication. During the study, participants undergo regular assessments including blood tests to monitor disease status and treatment effects. Researchers measure progression-free survival as the primary outcome, along with other outcomes such as minimal residual disease, overall response, survival rates, and time until next treatment. The study involves randomized assignment to treatment groups and continues through multiple cycles, with monitoring extending up to 50 months after the first patient is included.

Age: 18Years - 120YearsAll GendersPhase 3
30 locations
P

Actively Recruiting

Researchers are evaluating the safety and performance of the TriClip System, a device used for tricuspid transcatheter edge-to-edge repair TEER, in people with tricuspid regurgitation TR. This study is a prospective, observational, single-arm, multi-center post-market trial conducted in a real-world setting, following the devices approved uses. The goal is to confirm how the TriClip System works and how safe it is when used according to its approved indications. Participants who are eligible will undergo the TriClip procedure using the commercially available device. Follow-up visits will take place at hospital discharge, 30 days, 6 months by telephone, 12 months, and then annually up to 5 years. A special echocardiographic core laboratory will review heart ultrasound images for evaluation. Additionally, a subset of up to 250 participants at selected sites will take part in an imaging substudy involving cardiac-gated computed tomography CT scans at the start and after 12 months to assess heart remodeling. During the study, participants will be assessed before the procedure for eligibility. After the procedure, they will be monitored through scheduled visits and telephone calls to track safety and heart function. The main outcomes measured include rates of adverse events within 30 days post-procedure, improvements in tricuspid regurgitation severity, and quality of life scores at 30 days. This long-term follow-up will continue through 5 years to understand ongoing safety and performance of the device.

Age: 18Years +All Genders
9 locations
S

Actively Recruiting

Researchers are evaluating how well once-weekly insulin icodec maintains blood sugar levels compared to daily basal insulin injections in adults with type 2 diabetes. The study focuses on people who need to start basal insulin treatment after using other glucose-lowering medications. This phase 4 trial aims to assess insulin icodecs effectiveness in real-world clinical practice over about 13 months. Participants will be randomly assigned to receive either weekly subcutaneous injections of insulin icodec or daily subcutaneous injections of basal insulin analogues such as insulin glargine, detemir, or degludec. The study compares these two insulin regimens as part of standard type 2 diabetes care. Treatment continues during the 52-week period to monitor blood sugar control and treatment satisfaction. Throughout the study, participants will undergo assessments including measuring changes in glycated hemoglobin HbA1c from baseline to week 52. They will also complete questionnaires on treatment adherence, satisfaction, and burden, and researchers will track severe hypoglycemia episodes and insulin doses. The trial spans about 13 months, providing thorough monitoring of treatment impact and safety in daily clinical use.

Age: 18Years +All GendersPhase 4
75 locations
P

Actively Recruiting

This research aims to evaluate the effectiveness and safety of zanidatamab combined with a physicians choice of chemotherapy compared to trastuzumab combined with chemotherapy in treating adults with metastatic HER2-positive breast cancer who have either progressed on or cannot tolerate previous trastuzumab deruxtecan T-DXd treatment. Zanidatamab has shown promising results against various HER2-positive advanced tumors, including metastatic breast cancer, and may serve as a potential treatment option for these patients. The study also investigates patient-reported tolerability and physical functioning, as well as the pharmacokinetics and immune response to zanidatamab with chemotherapy. Participants will be randomly assigned to receive either zanidatamab or trastuzumab, each given by intravenous infusion alongside one of several chemotherapy options chosen by the physician eribulin, vinorelbine, gemcitabine, or capecitabine the latter is taken orally. Treatment will be administered according to the assigned group, and the study is open-label and multicenter, designed to compare these two treatment combinations in this patient population. During the study, participants will undergo regular assessments to monitor disease progression using imaging criteria RECIST version 1.1, evaluate survival, treatment response, and duration of response. Safety and side effects will be tracked through adverse event reporting and patient questionnaires on symptoms and physical function. Blood samples will be collected to study drug levels and immune reactions. Participants will be followed until disease progression, death, or for up to approximately 44 months for key outcomes, with overall survival monitored for up to about 80 months.

Age: 18Years +All GendersPhase 3
166 locations
C

Actively Recruiting

Researchers are studying the safety and effectiveness of pirtobrutinib LOXO-305 compared to ibrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study includes participants who may or may not have received prior treatment for their cancer and focuses on those with specific genetic markers, like 17p deletions, in one part of the trial. This is a phase 3, open-label study sponsored by Loxo Oncology, Inc. Participants receive either pirtobrutinib or ibrutinib as oral treatments. The study has two parts Part 1 compares pirtobrutinib and ibrutinib in a broad group of participants and may last up to six years, while Part 2 evaluates pirtobrutinib alone in treatment-nafve participants with 17p deletions for up to two years. Treatments are taken by mouth, and participants are randomly assigned to treatment groups. During the study, participants will undergo regular assessments to monitor their response to treatment, including checking for complete or partial remission. Researchers will evaluate progression-free survival, overall survival, duration of response, and tolerability over several years. Safety and effectiveness are closely tracked with scheduled visits and tests until data cutoff or disease progression. Participation can last up to six years depending on the study part.

Age: 18Years +All GendersPhase 3
143 locations
N

Actively Recruiting

Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.

Age: 18Years - 100YearsAll Genders
69 locations

1-10 of 67

1